Phospho-RPS6KB1 (Thr421) Antibody

What is Phospho-RPS6KB1 (Thr421) Antibody and what cellular pathway does it target?

Phospho-RPS6KB1 (Thr421) Antibody is a research reagent designed to specifically detect the phosphorylated form of ribosomal protein S6 kinase beta-1 (RPS6KB1, also known as p70 S6 kinase) at the threonine 421 phosphorylation site. RPS6KB1 functions as a serine/threonine kinase within the PI3K/mTOR signaling pathway, which plays a critical role in regulating protein synthesis in response to growth factors and nutrients . The antibody recognizes the specific peptide sequence around the phosphorylation site of threonine 421 (P-R-T(p)-P-V) in the human p70 S6 Kinase protein . This phosphorylation is part of a cascade of events that ultimately leads to the phosphorylation of ribosomal protein S6, which facilitates the translation of 5'-terminal oligopyrimidine tract mRNAs and contributes to cell proliferation, growth, and survival mechanisms .

What are the common applications for Phospho-RPS6KB1 (Thr421) Antibody in research?

Phospho-RPS6KB1 (Thr421) Antibody is utilized across multiple research applications:

• Western Blot (WB): For detection and quantification of phosphorylated RPS6KB1 in protein lysates, typically at dilutions of 1:500-1:2000

• Immunohistochemistry (IHC): For visualizing the localization of phosphorylated RPS6KB1 in tissue sections, using dilutions of 1:50-1:300

• Immunofluorescence (IF): For cellular localization studies with fluorescent detection, typically at dilutions of 1:50-1:200

• ELISA: For quantitative measurement of phosphorylated RPS6KB1 in biological samples

• Proximity Ligation Assay: For sensitive detection of protein phosphorylation events in situ, allowing visualization of individual phosphorylated proteins within cells

These applications enable researchers to study the activation status of the mTOR pathway, cellular responses to various stimuli, and dysregulation in pathological conditions.

How do I properly store and handle Phospho-RPS6KB1 (Thr421) Antibody to maintain its efficacy?

Proper storage and handling are crucial for maintaining antibody efficacy:

• Storage temperature: Store at -20°C or -80°C for long-term preservation

• Formulation: The antibody is typically supplied at 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, with 0.02% sodium azide and 50% glycerol as stabilizers

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles which can degrade antibody quality and reduce reactivity

• Aliquoting: Upon receipt, consider dividing the antibody into small working aliquots before freezing to minimize freeze-thaw cycles

• Working dilution preparation: Prepare dilutions fresh on the day of use in appropriate buffers with blocking agents

• Storage duration: Most antibodies remain stable for up to 1 year from the date of receipt when stored properly

Following these guidelines will help ensure experimental reproducibility and maximize the lifespan of your antibody reagent.

How should I design controls for experiments using Phospho-RPS6KB1 (Thr421) Antibody?

Designing appropriate controls is essential for rigorous experimental validation:

• Positive control: Include lysates from cells treated with agents known to induce RPS6KB1 phosphorylation at Thr421, such as:

  • Serum stimulation after starvation

  • Insulin treatment (10-100 nM for 15-30 minutes)

  • EGF treatment (50-100 ng/ml for 15-30 minutes)

• Negative control: Include samples with reduced RPS6KB1 phosphorylation:

  • Lysates from cells treated with mTOR inhibitors (rapamycin, torin)

  • Lysates from cells treated with specific RPS6KB1 inhibitors like LY2584702

  • Serum-starved cells

• Antibody specificity controls:

  • Blocking peptide competition: Pre-incubate antibody with the immunizing phosphopeptide

  • Dephosphorylation control: Treat lysates with lambda phosphatase

  • Total RPS6KB1 antibody in parallel to compare total protein levels to phosphorylated form

• Sample preparation controls:

  • Include phosphatase inhibitors in lysis buffers

  • Process all samples consistently to avoid artificial differences in phosphorylation

These controls will help verify that observed signals truly represent phosphorylated RPS6KB1 at Thr421 and not non-specific binding or artifacts.

What are the optimal sample preparation methods for detecting Phospho-RPS6KB1 (Thr421)?

Optimal sample preparation is critical for successful phosphoprotein detection:

• Cell lysis buffer composition:

  • Use buffers containing strong phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Include protease inhibitors to prevent protein degradation

  • Recommended buffer: RIPA or NP-40 buffer supplemented with phosphatase inhibitor cocktail

• Tissue processing:

  • Flash-freeze tissues immediately after collection

  • Homogenize tissues in cold lysis buffer containing phosphatase inhibitors

  • Maintain samples at 4°C throughout processing

• Protein quantification:

  • Perform protein quantification using methods compatible with detergents and phosphatase inhibitors

  • Load equal amounts of protein for comparative analyses

• Sample handling:

  • Process samples quickly to minimize phosphate loss

  • Avoid multiple freeze-thaw cycles of lysates

  • Add SDS sample buffer and heat immediately after lysis when possible

• Western blot considerations:

  • Use freshly prepared transfer buffer

  • Consider using PVDF membranes for better protein retention

  • Block with BSA rather than milk (milk contains phosphoproteins that can interfere)

Following these procedures will maximize the probability of preserving phosphorylation status during sample preparation.

What are the recommended dilutions and protocols for different experimental applications?

These recommendations serve as starting points and may require optimization for specific experimental conditions.

How can I differentiate between phosphorylation of RPS6KB1 at Thr421 versus other phosphorylation sites?

Differentiating between various phosphorylation sites on RPS6KB1 requires careful experimental design:

• Antibody selection: Use highly specific antibodies that recognize only the Thr421 site, validated through phosphopeptide arrays or other specificity tests. The antibody should be tested against other phosphorylation sites (T389, S411, S418, S424, etc.) to confirm its specificity .

• Phosphorylation site-specific inhibitors:

  • mTOR inhibitors primarily affect Thr389 phosphorylation

  • PDK1 inhibitors affect Thr229 phosphorylation

  • Compare effects of various inhibitors on Thr421 versus other sites

• Phosphorylation site mutants:

  • Generate T421A (non-phosphorylatable) mutants

  • Create phosphomimetic (T421D or T421E) mutants

  • Compare antibody reactivity against wild-type and mutant forms

• Mass spectrometry validation:

  • Perform phospho-enrichment followed by mass spectrometry

  • Quantify site-specific phosphorylation

  • Confirm antibody specificity with orthogonal methods

• Sequential immunoprecipitation:

  • First IP with total RPS6KB1 antibody

  • Then probe with site-specific phospho-antibodies

  • Compare phosphorylation patterns under different conditions

These approaches help ensure that observed signals are specific to Thr421 phosphorylation rather than other phosphorylation sites on RPS6KB1.

What is the functional significance of RPS6KB1 phosphorylation at Thr421 compared to other phosphorylation sites?

The phosphorylation of RPS6KB1 occurs at multiple sites with distinct functional roles:

• Thr421 phosphorylation:

  • Located in the autoinhibitory domain

  • Contributes to relief of autoinhibition

  • Often phosphorylated in conjunction with Ser424 by proline-directed kinases

  • Serves as a priming event for subsequent phosphorylation events

  • Linked to cell cycle regulation and mitogenic responses

• Comparative significance:

  • Thr389 phosphorylation (in the hydrophobic motif) is considered the primary indicator of RPS6KB1 activation and correlates with kinase activity

  • Thr229 phosphorylation (in the activation loop) is required for full activation

  • Thr421/Ser424 phosphorylation precedes Thr389 phosphorylation in the activation sequence

  • Ser411 phosphorylation is involved in nuclear-cytoplasmic shuttling

• Pathway-specific regulation:

  • Thr389 is primarily regulated by mTORC1

  • Thr421/Ser424 can be phosphorylated by ERK and other MAPK pathway components

  • This differential regulation allows for integration of multiple signaling inputs

• Clinical relevance:

  • Hyperphosphorylation of RPS6KB1 at Thr389 has been associated with poor prognosis in NSCLC

  • The prognostic significance of Thr421 phosphorylation is less well characterized

  • Combined assessment of multiple phosphorylation sites may provide more comprehensive pathway activation status

Understanding the relative contributions of each phosphorylation site helps in interpreting experimental results and developing targeted therapeutic approaches.

How can I use Proximity Ligation Assay (PLA) to quantify RPS6KB1 phosphorylation in situ?

Proximity Ligation Assay offers a sensitive method for visualizing and quantifying protein phosphorylation events:

• Principle and advantages:

  • PLA can detect single molecules of phosphorylated protein in fixed cells

  • Each red dot in the assay represents one phosphorylated RPS6KB1 molecule

  • Higher specificity than conventional immunofluorescence due to dual antibody recognition

• Required reagents:

  • Rabbit polyclonal anti-phospho-RPS6KB1 (Thr421) antibody

  • Mouse monoclonal anti-RPS6KB1 (total protein) antibody

  • PLA probes (anti-rabbit PLUS and anti-mouse MINUS)

  • Ligation and amplification reagents

• Protocol overview:

  • Fix and permeabilize cells

  • Block non-specific binding

  • Incubate with primary antibodies (1:1200 dilution for rabbit polyclonal and 1:50 for mouse monoclonal)

  • Add PLA probes and perform ligation

  • Conduct rolling circle amplification with fluorescently-labeled nucleotides

  • Counterstain nuclei and image

• Quantification:

  • Analyze images using specialized software like BlobFinder from the Centre for Image Analysis at Uppsala University

  • Quantify number of dots per cell as a measure of phosphorylation level

  • Compare between experimental conditions

• Controls:

  • Omit one primary antibody as negative control

  • Use stimulated cells (e.g., insulin treatment) as positive control

  • Include phosphatase-treated samples as additional negative control

This approach provides spatial information about phosphorylation events that is not possible with biochemical methods like Western blotting.

What are common issues when using Phospho-RPS6KB1 (Thr421) Antibody and how can they be resolved?

Addressing these issues requires systematic troubleshooting and careful optimization of experimental conditions.

How should I interpret changes in RPS6KB1 phosphorylation at Thr421 in the context of other pathway components?

Proper interpretation of RPS6KB1 phosphorylation data requires consideration of the broader signaling context:

• Upstream regulators:

  • Assess PI3K/Akt pathway activation (phospho-Akt status)

  • Check mTORC1 activity (phospho-S6, phospho-4EBP1)

  • Evaluate MAPK pathway involvement (phospho-ERK)

  • These upstream components can influence Thr421 phosphorylation through different mechanisms

• Parallel phosphorylation events:

  • Compare Thr421 phosphorylation with Thr389 phosphorylation

  • Thr389 is more directly regulated by mTORC1 and correlates better with kinase activity

  • Discrepancies between sites can indicate differential pathway activation

• Downstream targets:

  • Measure phosphorylation of S6 ribosomal protein (Ser235/236)

  • Assess protein synthesis rates if relevant

  • Evaluate cell cycle progression markers

• Context-specific considerations:

  • In cancer cells, hyperphosphorylation of RPS6KB1 can indicate overactivation of mTOR signaling

  • In response to nutrients, RPS6KB1 phosphorylation should correlate with nutrient availability

  • During cell cycle progression, phosphorylation patterns may change in a phase-dependent manner

• Functional correlation:

  • Always link phosphorylation data to functional outcomes (proliferation, survival, protein synthesis)

  • Consider the possibility of compensatory mechanisms

This integrated approach helps avoid misinterpretation of isolated phosphorylation events.

What are the implications of RPS6KB1 hyperphosphorylation in cancer research and how can Phospho-RPS6KB1 (Thr421) Antibody be used for prognostic studies?

RPS6KB1 hyperphosphorylation has significant implications for cancer research:

These findings highlight the importance of phosphorylation-specific antibodies in translational cancer research.

How is Phospho-RPS6KB1 (Thr421) Antibody being used in combination with other research tools for pathway analysis?

Researchers are increasingly combining phospho-specific antibodies with other advanced tools:

• Multi-parameter flow cytometry:

  • Simultaneous detection of multiple phosphorylation events at single-cell resolution

  • Correlation of RPS6KB1 phosphorylation with cell cycle markers

  • Analysis of pathway activation in heterogeneous cell populations

• CRISPR/Cas9-mediated genome editing:

  • Generation of phospho-site mutants (T421A, T421E)

  • Analysis of phosphorylation site interdependence

  • Creation of cellular models for studying site-specific functions

• Phosphoproteomics integration:

  • Validation of mass spectrometry-identified phosphorylation events

  • Correlation of Thr421 phosphorylation with global phosphorylation changes

  • Identification of novel pathway connections

• Live-cell imaging:

  • Use with phosphorylation-sensitive fluorescent reporters

  • Real-time monitoring of kinase activity in living cells

  • Spatial and temporal dynamics of pathway activation

• Single-cell analysis:

  • Assessment of phosphorylation heterogeneity within tissues

  • Correlation with cellular phenotypes and states

  • Identification of rare cell populations with altered signaling

These integrated approaches provide more comprehensive understanding of RPS6KB1 signaling dynamics than antibody-based detection alone.

What are the considerations for using Phospho-RPS6KB1 (Thr421) Antibody in different model organisms and systems?

When applying phospho-specific antibodies across different biological systems, several considerations are important:

• Sequence conservation:

  • The region around Thr421 is highly conserved in mammals (human, mouse, rat)

  • Verify epitope sequence conservation before using in non-mammalian models

  • Consult sequence alignments to identify potential cross-reactivity

• Validation requirements:

  • Perform species-specific validation experiments

  • Include positive controls known to induce phosphorylation in that species

  • Consider knockout/knockdown controls where available

• Model-specific protocols:

  Model System	Special Considerations
  Mouse/Rat models	Harvest tissues rapidly and snap-freeze; process with phosphatase inhibitors
  Cell lines	Different cell types may require optimization of stimulation conditions
  Patient-derived xenografts	Rapid processing essential; consider phosphorylation stability during implantation
  3D organoids	May require modified fixation protocols; consider penetration of antibodies
  Primary cultures	May show different pathway regulation compared to established cell lines

• Pathway conservation:

  • Upstream regulators of Thr421 phosphorylation may differ between species

  • Functional consequences may vary in different biological contexts

  • Interpret results in the context of species-specific signaling networks

• Technical adaptations:

  • Adjust tissue fixation and processing for specific model systems

  • Optimize antigen retrieval for different tissue types

  • Consider tissue-specific autofluorescence in IF applications

These considerations ensure appropriate application and interpretation of results across diverse experimental systems.

How can phosphorylation of RPS6KB1 at Thr421 be targeted therapeutically, and how might Phospho-RPS6KB1 (Thr421) Antibody be used to monitor treatment efficacy?

Targeting RPS6KB1 phosphorylation represents a promising therapeutic approach:

• Therapeutic strategies:

  • Direct RPS6KB1 inhibitors (e.g., LY2584702) that block kinase activity

  • mTOR inhibitors (rapamycin and analogs) that indirectly reduce RPS6KB1 phosphorylation

  • Dual PI3K/mTOR inhibitors that target upstream pathway activation

  • Combination approaches targeting multiple pathway components

• Monitoring treatment efficacy:

  • Phospho-RPS6KB1 (Thr421) Antibody can serve as a pharmacodynamic biomarker

  • Reduced phosphorylation indicates target engagement and pathway inhibition

  • Serial biopsies allow temporal monitoring of drug effects

  • Correlation with clinical response helps establish predictive biomarkers

• Methodological approaches:

  • Immunohistochemistry on pre- and post-treatment biopsies

  • Western blotting on patient-derived cells exposed to therapy

  • PLA for sensitive detection of changes in phosphorylation status

  • Integration with downstream markers (phospho-S6) for pathway activity assessment

• Research findings:

  • Inhibition of RPS6KB1 phosphorylation has been shown to suppress cancer cell proliferation

  • RPS6KB1 dephosphorylation promotes G0-G1 cell cycle arrest and increases apoptosis

  • These effects have been demonstrated in lung adenocarcinoma (A549) and squamous cell carcinoma (SK-MES-1) cell lines

• Challenges and considerations:

  • Feedback mechanisms may restore pathway activity despite initial inhibition

  • Heterogeneous tumor responses require single-cell analysis approaches

  • Combination with other biomarkers may improve predictive value

  • Standardization of phosphorylation assessment is needed for clinical application

Phospho-specific antibodies thus play a dual role in drug development: identifying potential targets and monitoring treatment efficacy.